# Alternate Day Buprenorphine Administration, Phase XII - 17

> **NCT00000235** · PHASE2 · COMPLETED · sponsor: **National Institute on Drug Abuse (NIDA)**

## Conditions studied

- Opioid-Related Disorders

## Interventions

- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT00000235
- **Lead sponsor:** National Institute on Drug Abuse (NIDA)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (—)
- **Last updated:** 2005-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000235, "Alternate Day Buprenorphine Administration, Phase XII - 17". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00000235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*